| Eosinophilic annular erythema is a rare, pruritic disease characterized by a chronic course and frequent resistance to treatment. |
| There is a need for effective and safe therapeutic options for the management of eosinophilic annular erythema. |
| Targeting cytokines crucial for the functioning of eosinophils, mainly interleukin-5, may be a novel direction in the treatment of eosinophilic annular erythema, but prospective, double-blinded and placebo-controlled studies are needed to provide further evidence. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.